Efficacy and safety of adjuvant therapy with PD‑1/PD‑L1 inhibitors in cancer

Anti-programmed cell death protein-1 (PD-1)/programmed cell death 1 ligand 1 (PD-L1) antibodies have been widely used in cancers. The present study aimed to evaluate the efficacy and safety of PD-1/PD-L1 inhibitors in human cancers. Studies were searched from Cochrane Library, PubMed and Embase data...

Descripción completa

Detalles Bibliográficos
Autores principales: Mo, Dun-Chang, Liang, Zi-Yu, Chen, Long, Huang, Jian-Feng, Luo, Peng-Hui, Wang, Han-Lei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2022
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9748656/
https://www.ncbi.nlm.nih.gov/pubmed/36561965
http://dx.doi.org/10.3892/etm.2022.11685

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9748656/
https://www.ncbi.nlm.nih.gov/pubmed/36561965
http://dx.doi.org/10.3892/etm.2022.11685

Ejemplares similares